U.S., Oct. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07199413) titled 'Allogeneic, Antigen-Presenting, GM-CSF-secreting, SV-BR-1-GM Whole Cell-Therapeutic Vaccine and Immunotherapy: A Phase I Pilot Safety and Feasibility Study for Solid Tumor Patients With CNS Metastases' on Sept. 22.
Brief Summary: This is a prospective, single-center, phase 1 basket trial that will evaluate the safety and feasibility of administering SV-BR-1-GM in combination with pembrolizumab to solid tumor oncology patients over nine cycles.
Study Start Date: March 01, 2026
Study Type: INTERVENTIONAL
Condition:
Brain Metastases
Leptomeningeal Metastasis
Intervention:
BIOLOGICAL: SV-BR-1-GM Vaccine
~20 X 10^6 cells across 4 i...